Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Bright Minds Biosciences Inc

Healthcare CA DRUG

94.04CAD
-0.85(0.90%)

Last update at 2026-06-24T18:48:00Z

Day Range

93.6094.04
LowHigh

52 Week Range

33.01170.00
LowHigh

Fundamentals

  • Previous Close 94.89
  • Market Cap1152.73M
  • Volume210
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.76

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Income before tax -12.22935M -2.80195M -7.37223M -14.96494M -8.65076M
Minority interest - - - - -
Net income -12.22935M -2.80195M -7.37223M -14.96494M -8.65076M
Selling general administrative 2.57M 1.45M 2.20M 2.55M 2.47M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.08M 0.07M 0.07M 0.00604M 0.00000M
Ebit - - - -14.73201M -8.78620M
Ebitda - - - -14.72598M -
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -13.93758M -2.82277M -7.38641M -14.73201M -8.78620M
Other operating expenses - - - - -
Interest expense - - - - 0.00000M
Tax provision - - - - -
Interest income 1.52M 0.03M 0.00000M 0.00000M -
Net interest income 1.52M 0.03M 0.00000M 0.00000M -0.01867M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 13.94M 2.82M 7.39M 14.73M 8.79M
Cost of revenue - - - - -
Total other income expense net 0.19M -0.00931M 0.01M -0.23293M 0.15M
Discontinued operations - - - - -
Net income from continuing ops -12.22935M -2.80195M -7.37223M -14.96494M -8.65076M
Net income applicable to common shares - - - -14.96494M -8.65076M
Preferred stock and other adjustments - - - - -
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total assets 84.42M 6.10M 6.88M 12.09M 20.04M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - - - - -
Total liab 2.38M 0.57M 0.28M 1.54M 0.64M
Total stockholder equity 82.04M 5.54M 6.60M 10.54M 19.40M
Deferred long term liab - - - - -
Other current liab - - - - -
Common stock - - - 32.24M 27.08M
Capital stock 123.25M 35.42M 33.91M 32.24M 27.08M
Retained earnings -46.57832M -34.34897M -31.54702M -24.17480M -9.20986M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 82.91M 5.72M 6.75M 11.63M 19.76M
Cash and equivalents - - - - -
Total current liabilities 2.34M 0.53M 0.28M 1.47M 0.64M
Current deferred revenue - - - - -
Net debt - - - - -
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity - - - 2.48M 1.53M
Property plant equipment - - - 0.14M -
Total current assets 84.31M 5.99M 6.81M 11.95M 20.04M
Long term investments - - - - -
Net tangible assets - - - 10.54M 19.40M
Short term investments - - - - -
Net receivables - - - 0.16M 0.11M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 1.71M 0.41M 0.18M 1.25M 0.60M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 0.11M 0.12M 0.07M 0.14M 0.00200M
Capital lease obligations 0.13M 0.12M 0.07M 0.14M 0.00000M
Long term debt total - - - - -
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Investments - - - - -
Change to liabilities - - - 0.77M 0.51M
Total cashflows from investing activities - - - - -
Net borrowings -0.10015M -0.08973M -0.08611M -0.00716M -0.00716M
Total cash from financing activities 85.57M 0.81M 2.19M 5.20M 26.06M
Change to operating activities - - - -0.04186M -0.20007M
Net income -12.22935M -2.80195M -7.37223M -14.96494M -8.65076M
Change in cash 76.88M -1.03961M -4.83458M -8.13210M 18.96M
Begin period cash flow 5.72M 6.75M 11.63M 19.76M 0.80M
End period cash flow 82.91M 5.72M 6.75M 11.63M 19.76M
Total cash from operating activities -8.69162M -1.85019M -7.02426M -13.58712M -7.31930M
Issuance of capital stock 82.10M 0.90M 1.22M 4.03M 27.74M
Depreciation 0.08M 0.07M 0.07M 0.00604M 0.00604M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities - - - -0.79998M -1.78663M
Change to netincome - - - 0.65M 1.03M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.55M 0.04M -0.94172M 0.73M 0.31M
Stock based compensation 3.18M 0.84M 1.15M 0.88M 0.88M
Other non cash items 0.04M 0.00894M 0.02M 0.03M 0.37M
Free cash flow -8.69162M -1.85019M -7.02426M -13.58712M -7.31930M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
DRUG
Bright Minds Biosciences Inc		 -0.85 0.90% 94.04 - - - 13.50 -0.098
METX
METX		 - -% 1.99 - - - 72.00
TELI
Telescope Innovations Corp.		 0.06 7.23% 0.89 - - 4.32 6.45 4.32 -1.62
DTC
Defence Therapeutics Inc		 -0.04 7.27% 0.51 - - - 89.80 -9.991
LOBE
Lobe Sciences Ltd		 - -% 0.09 - - 2.44 15.58 5.75 1.64

Reports Covered

Stock Research & News

View All

Profile

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

Bright Minds Biosciences Inc

19 Vestry Street, New York, NY, United States, 10013

Key Executives

Name Title Year Born
Mr. Ian McDonald Co-Founder, CEO, President & Director 1988
Dr. Jan Torleif Pedersen M.Sc., Ph.D. Chief Science Officer & Director 1965
Mr. Alex Vasilkevich COO & Senior Scientific Officer 1988
Dr. Emer Leahy M.B.A., Ph.D. Consultant 1967
Dr. Stephen D. Collins M.D., Ph.D. Chief Medical Officer 1952
Mr. Alex Vasilkevich COO & Senior Scientific Officer 1989
Dr. Stephen D. Collins M.D., Ph.D. Chief Medical Officer 1953

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions